Register
Login:
Share:
Email Facebook Twitter


EXCLUSIVE: Alastair Smith, Avacta Group CEO gives an Operational Update


Glaxosmithkline Share Price (GSK)



Share Price Information for Glaxosmithkline (GSK)


Share Price: 1,501.00Bid: 1,501.00Ask: 1,501.40Change: 15.20 (+1.02%)Riser - Glaxosmithkline
Spread: 0.40Spread as %: 0.03%Open: 1,492.80High: 1,503.20Low: 1,492.60Yesterday’s Close: 1,485.80

Glaxosmithkline Plc Ord 25P

Glaxosmithkline is listed in the FTSE 100, FTSE All-Share, FTSE 350, FTSE 350 High Yield
Glaxosmithkline is part of the Medicine and Biotech Research sector

Glaxosmithkline has a share of around 5% of the world's pharmaceutical market, aiming to tackle 3 of the 'priority' diseases identified by the World Health Organisation. The company employs around 96,500 people in over 100 countries. In 2010 they delivered 1.4 billion vaccine doses to 179 countries.





Share Price SpacerPrice
1501.00
Share Price SpacerBid
1501.00
Share Price SpacerAsk
1501.40
Share Price SpacerChange
1.02%15.20
Share Price SpacerVolume
748,887
Share Price SpacerOpen
1,492.80
Share Price SpacerHigh
1,503.20
Share Price SpacerLow
1,492.60
Share Price SpacerClose
1,485.80
Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 4,960.00m £74,449.65m 1,500

52 Week High 1,625.00 52 Week High Date 21-AUG-2018
52 Week Low 1,236.40 52 Week Low Date 6-FEB-2018

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
1,520 363,946 261,710 47.803 31.40 80.00 5.33


London South East Users info for Glaxosmithkline


Users who watch GSK also watch: Lloyds, BP, Vodafone, Tesco, Barclays, RBS, HSBC, National Grid, BT, Aviva

Users who hold GSK also hold: Vodafone, BP, Lloyds, National Grid, Royal Dutch Shell B, Tesco, HSBC, Aviva, BT, Centrica


Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

21-Sep-18
09:37:51
1,501.00
239
Buy* 
1,500.80
1,501.00
3,587
Trade Type:
Automatic execution

21-Sep-18
09:37:51
1,501.00
252
Buy* 
1,500.80
1,501.00
3,783
Trade Type:
Automatic execution

21-Sep-18
09:37:51
1,501.00
410
Sell* 
1,501.00
1,501.20
6,154
Trade Type:
Automatic execution




View more Glaxosmithkline trades >>

Directors Deals for Glaxosmithkline (GSK)
Trade DateActionNotifierPriceCurrencyAmountHolding
11-Sep-18Buy
Trade Notifier Information for GlaxoSmithKline
Emma Walmsley held the position of CEO at GlaxoSmithKline at the time of this trade.
 Emma Walmsley
1497.17GBX8204432
11-Sep-18Buy
Trade Notifier Information for GlaxoSmithKline
Simon Dingemans held the position of CFO at GlaxoSmithKline at the time of this trade.
 Simon Dingemans
1497.17GBX817759225
11-Sep-18Buy
Trade Notifier Information for GlaxoSmithKline
David Redfern held the position of Chief Strategy Officer at GlaxoSmithKline at the time of this trade.
 David Redfern
1497.17GBX8136735
View more Glaxosmithkline directors dealings >>


Craigl
Posts: 4,164
Opinion:No Opinion
Price:1,484.20
RE: why the drop?
Sun 10:08
Ha Ha
AllAtSea
Posts: 610
Opinion:No Opinion
Price:1,484.20
RE: why the drop?
Sun 07:37
Ssshhh! Don't tell anyone..
Craigl
Posts: 4,164
Opinion:No Opinion
Price:1,484.20
RE: why the drop?
Sat 22:30
Look at the history of this share it drops to 12 to 13 then goes back up to 16 area . A great predictable share
Pokerchips
Posts: 5,186
Opinion:No Opinion
Price:1,484.20
RE: New AIDS Treatment
Sat 12:30
To be clear...it isnt an AIDS treatment ...it is an HIV treatment which helps prevent the possible onset of AIDS in patients who have been diagnosed HIV+
Inkose
Posts: 10
Opinion:No Opinion
Price:1,484.20
New AIDS Treatment
Sat 10:40
Glaxosmithkline said its ViiV Healthcare joint venture had submitted a marketing authorisation application to the European Medicines Agency for a single-tablet, two-drug regimen for the treatment of HIV. The submission was based on studies that included more than 1400 infected adults, the results of which were presented at the 2018 International AIDS Society meeting in July. A new drug application to the US FDA was planned for the single tablet regimen for October. Other global regulatory submissions of dolutegravir and lamivudine as a single-tablet, two-drug regimen were anticipated in the coming months. At 1:09pm: (LON:GSK) GlaxoSmithKline PLC share price was -9.7p at 1485.9p Story provided by StockMarketWire.com
View more share chat for Glaxosmithkline (GSK) >>




Glaxosmithkline Plc Ord 25P home pageWebsite: Glaxosmithkline Plc Ord 25P
Website Description: GlaxoSmithKline has a share of around 5% of the world's pharmaceutical market, aiming to tackle 3 of the 'priority' diseases identified by the World Health Organisation. The company employs around 99,300 people in over 100 countries. In 2010 they delivered 1.4 billion vaccine doses to 179 countries. As of August 2016 it had a market capitalisation of £81 billion the fourth largest on the London Stock Exchange



Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.